Publications & Works

Publication Network
Articles 140
All (140)
SCI-E, SSCI, AHCI (109)
SCI-E, SSCI, AHCI, ESCI (116)
ESCI (7)
Scopus (118)
TRDizin (30)
Other Publications (1)

1. Concordance between multidisciplinary tumor board decisions and AI-based recommendations in endometrial cancer: impact of discordance direction on clinical outcomes.

Aliyev V., Cebeci S., Birsin Z., Günaltılı M., Fidan M. C., Çerme E., et al.
Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico , 2026 (SCI-Expanded, Scopus)

2. Baseline Serum Albumin-to-Creatinine Ratio as an Independent Prognostic Marker in De Novo Metastatic HER2-negative Gastric Cancer

Günaltılı M., Guliyev M., Birsin Z., Çerme E., Aliyev V., Abbasov H., et al.
Journal of oncological sciences , vol.12, pp.1-8, 2026 (TRDizin) Creative Commons License

3. Comparative Real-World Safety Profiles of Fibroblast Growth Factor Receptor Inhibitors: A Pharmacovigilance Study.

Evinç S. J., Akmercan Ç. E., Birsin Z., Cebeci S., Çerme E., Aliyev V., et al.
Asia-Pacific journal of clinical oncology , 2026 (SCI-Expanded, Scopus)

4. Kaposi Sarcoma as a Cause of Anemia in Kidney Transplant Recipients: Two Case Reports.

Alan A. M., Murt A., Dincer M. T., Cerme M. O., Eskazan T., Ergun S., et al.
Transplantation proceedings , 2026 (SCI-Expanded, Scopus)

5. Association between obesity and outcomes of first-line CDK4/6 inhibitor therapy in metastatic breast cancer: a multicenter real-world study.

Günaltılı M., Guliyev M., Birsin Z., Çerme E., Aliyev V., Şen G. A., et al.
Scientific reports , 2026 (SCI-Expanded, Scopus)

6. Long-term outcomes of rare pure histological subtypes of breast cancer in a tertiary single-center retrospective cohort.

Fidan M. C., Guliyev M., Günaltılı M., Birsin Z., Çiçek E., Abbasov H., et al.
Discover oncology , 2026 (SCI-Expanded)

7. Real-world comparison of androgen receptor pathway ınhibitors versus docetaxel as first-line treatment in metastatic hormone-sensitive prostate cancer.

Birsin Z., Aliyev V., Cebeci S., Guliyev M., Jeral Evinç S., Çerme E., et al.
Current medical research and opinion , pp.1-10, 2026 (SCI-Expanded, Scopus)

8. Burnout among caregivers of hospitalized medical oncology patients: A cross-sectional survey study.

Guzel S. S., Tay K., Demirci S. N., Alan Ö.
JOURNAL OF CLINICAL ONCOLOGY , vol.44, no.16_suppl, pp.1, 2026 (SCI-Expanded, Scopus) Creative Commons License

9. Nutritional and inflammatory factors associated with chemotherapy response and survival in advanced high-grade serous ovarian cancer: A machine learning–based analysis.

Birsin Z., Cebeci S., Jeral S., Çerme E., Aliyev V., Demirci S. N., et al.
JOURNAL OF CLINICAL ONCOLOGY , vol.44, no.16_suppl, pp.1, 2026 (SCI-Expanded, Scopus) Creative Commons License

10. Real-World Outcomes of CDK4/6 Inhibitors in Germline BRCA1/2-Mutated Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer: Turkish Oncology Group (TOG) Study

Seyyar M., Kalem A., Sali M., Karabuğa B., Sahin T. K., Dişli A. K., et al.
CURRENT ONCOLOGY , vol.33, no.6, pp.1-20, 2026 (SCI-Expanded, Scopus) Creative Commons License

11. Real-World Efficacy and Safety of Frontline Enfortumab Vedotin Plus Pembrolizumab in Metastatic Urothelial Carcinoma: A Multicenter Study and Review of the Literature

Kıkılı C. İ., Araz M., Ürün Y., Başaran M., Şener N., Yazar A., et al.
CLINICAL GENITOURINARY CANCER , vol.1, pp.1, 2026 (SCI-Expanded, Scopus)

12. Real-world outcomes of systemic therapy in patients with anaplastic thyroid carcinoma.

Alan Ö., Jeral S., Demirci S. N.
JOURNAL OF CLINICAL ONCOLOGY , vol.44, no.16_suppl, pp.1, 2026 (SCI-Expanded, Scopus) Creative Commons License

13. Real-World Outcomes and Prognostic Factors in Patients with Radioiodine-Refractory Differentiated Thyroid Cancer Treated with Sorafenib: A Multicenter Study

Atas Ipek S., Yaslikaya S., Kara I. O., Koseci T., Bayram E., Asarkaya E., et al.
JOURNAL OF CLINICAL MEDICINE , vol.15, no.13, pp.1-13, 2026 (SCI-Expanded, Scopus) Creative Commons License

14. Prognostic Impact of PET/CT-Derived Sarcopenia in Metastatic Breast Cancer Treated with CDK4/6 Inhibitors

Cebeci S., Birsin Z., Jeral Evinç S., Abbasov H., Aliyev V., Çerme E., et al.
JOURNAL OF CLINICAL MEDICINE , vol.15, no.10, pp.1-18, 2026 (SCI-Expanded, Scopus) Creative Commons License

15. Immune Checkpoint Inhibitor-Associated Immune-Mediated Nephropathy: A Real-World Pharmacovigilance Study

Mütiş Alan A., Murt A., Dinçer M. T., Trabulus S., Alan Ö., Altıparmak M. R.
JOURNAL OF CLINICAL MEDICINE , vol.15, no.10, pp.1-16, 2026 (SCI-Expanded, Scopus) Creative Commons License

16. Immune-Mediated upper gastrointestinal toxicities reported With immune checkpoint inhibitors: An analysis of the food and drug administration adverse event reporting system (FAERS)

Cerme E., Guliyev M., Aliyev V., Birsin Z., Günaltılı M., Fidan M. C., et al.
JOURNAL OF ONCOLOGY PHARMACY PRACTICE , vol.1, pp.1-8, 2026 (SCI-Expanded, Scopus)

17. Prognostic Impact and Clinicopathological Correlates of HER2 Status in Gastric Cancer: A Multicenter Retrospective Turkish Oncology Group Study

Yildirim S., Sever O. N., Turkoglu E., Sariyar Busery N., Dogan A., Baydas T., et al.
CLINICAL MEDICINE INSIGHTS: ONCOLOGY , vol.20, pp.1-23, 2026 (SCI-Expanded, Scopus) Creative Commons License

18. Does Surgical Timing After Neoadjuvant Anti-HER2 Therapy Affect Pathological Complete Response and Survival in HER2-Positive Breast Cancer? A Multicenter Retrospective Cohort Study.

Birsine Z., Alkan O., Bükün H. O., Nazlı İ., Günaltılı M., Çerme E., et al.
Journal of surgical oncology , 2026 (SCI-Expanded, Scopus)

19. Prognostic value of the pretreatment CA19-9/Albumin ratio in de novo metastatic colorectal cancer: A retrospective cohort study.

Günaltili M., Guliyev M., Birsin Z., Çerme E., Aliyev V., Abbasov H., et al.
Medicine , vol.105, no.15, 2026 (SCI-Expanded, Scopus)

20. Prognostic value of nutritional and inflammation-based scores in advanced soft tissue sarcoma treated with trabectedin: a multicenter study

Jeral Evinç S., Eyüpler Akmercan Ç., Cebeci S., Birsin Z., Nazlı İ., Güren A. K., et al.
FRONTIERS IN ONCOLOGY , vol.16, pp.1-10, 2026 (SCI-Expanded, Scopus) Creative Commons License

21. Co-reported respiratory adverse events in trastuzumab deruxtecan–associated interstitial lung disease: A pharmacovigilance analysis of the FAERS database

Jeral Evinç S., Eyüpler Akmercan Ç., Birsin Z., Cebeci S., Çerme E., Aliyev V., et al.
JOURNAL OF ONCOLOGY PHARMACY PRACTICE , vol.1, no.1, pp.1-9, 2026 (SCI-Expanded, Scopus)

22. Hemophagocytic Lymphohistiocytosis Associated with Immune Checkpoint Inhibitors: A Pharmacovigilance Analysis of Spontaneous Reports

Güzel S. S., Tay ., Çiçek E., Jeral Evinç S., Atal S., Papila Ç., et al.
CANCERS , vol.18, pp.1-14, 2026 (SCI-Expanded, Scopus) Creative Commons License

23. Capecitabine versus Paclitaxel After CDK4/6 Inhibitor Progression in Hormone Receptor–Positive, HER2-Negative Metastatic Breast Cancer: A Real-World Study

Birsin Z., Güren A. K., Aliyev V., Guliyev M., Jeral S., Cebeci S., et al.
BREAST CANCER: TARGETS AND THERAPY , vol.Volume 18, pp.1-13, 2026 (SCI-Expanded, Scopus) Creative Commons License

24. Oligoprogression During First-Line Treatment of Metastatic Hormone-Sensitive Prostate Cancer: Comparative Outcomes of Metastasis-Directed Radiotherapy and Systemic Treatment Change

Günaltılı M., Guliyev M., Birsin Z., Çerme E., Aliyev V., Abbasov H., et al.
JOURNAL OF CLINICAL MEDICINE , vol.15, no.8, pp.1-14, 2026 (SCI-Expanded, Scopus) Creative Commons License

25. Acute hemodialysis for cancer-associated acute kidney injury: etiologies, indications, and outcomes from a 25-year single-center experience

Mutis Alan A., Yalin S. F., Atas I., Alan Ö., Altiparmak M. R.
RENAL FAILURE , vol.48, no.1, pp.1-13, 2026 (SCI-Expanded, Scopus) Creative Commons License

26. Diagnostic utility and discriminative ability of cholesterol-modified prognostic nutritional index and inflammatory indicators in colorectal cancer: a retrospective case-control study

Papila B., Durmus S., Guliyev M., Alan Ö., Demirci N. S., Gelisgen R., et al.
SCIENTIFIC REPORTS , vol.1, pp.1-27, 2026 (SCI-Expanded, Scopus)

27. Tyrosine Kinase Inhibitor Therapy in Metastatic Medullary Thyroid Carcinoma: Real-World Data from Turkish Oncology Group

Yıldız S., Demir H., Özüdoğru T., Günenç D., Gökdere Z. S., Arvas H., et al.
JOURNAL OF CLINICAL MEDICINE , vol.15, no.6, pp.1-17, 2026 (SCI-Expanded, Scopus) Creative Commons License

28. Real-world efficacy of ramucirumab plus paclitaxel with or without nivolumabin patients with advanced gastric and gastroesophageal junction cancers

Köylü B., Kıkılı C. İ., Kemik ., Demir N., Alan Ö., Laçin Ş., et al.
Annals of Medical Research , vol.2026, no.33, pp.91-98, 2026 (TRDizin) Creative Commons License

29. Inflammatory and Nutritional Indices as Prognostic Markers in Locally Advanced Gastric Cancer Treated with Neoadjuvant FLOT: A Retrospective Multicenter Study

Yolcu S. T., Günaltılı M., Ayaz Yolcu E., Güzel S. S., ¸Sengül N., Atcı M. M., et al.
JOURNAL OF CLINICAL MEDICINE , vol.15, no.7, pp.1-19, 2026 (SCI-Expanded, Scopus) Creative Commons License

30. Prognostic Impact of Early Metabolic Response on Interim 18F-FDG PET/CT in HR+/HER2− Metastatic Breast Cancer Treated with CDK4/6 Inhibitors

Aliyev V., Güren A. K., Guliyev M., Birsin ., Günaltılı M., Fidan M. C., et al.
MEDICINA (KAUNAS, LITHUANIA) , vol.62, no.3, pp.11-14, 2026 (SCI-Expanded, Scopus) Creative Commons License

31. Real-world comparison of cabozantinib and sunitinib in advanced non-clear cell renal cell carcinoma: A multicenter study by the Turkish Oncology Group.

Şahin G., Tüzün E. K., Güzel H. G., Guliyev M., Dişli A. K., Yazıcı M., et al.
International journal of cancer , vol.158, pp.1067-1079, 2026 (SCI-Expanded, Scopus)

32. Evaluation of the efficacy and tolerability of bevacizumab-based treatments in recurrent primary brain tumors: a multicenter real-world Turkish Oncology Group (TOG) study.

Sucuoğlu İşleyen Z., Seçmeler Ş., Sakin A., Cihan Ş., Beşiroğlu M., Kahraman S., et al.
BMC cancer , 2026 (SCI-Expanded, Scopus)

33. Outcomes of First-Line PARP Inhibitor Therapy in Ovarian Cancer: A Multicenter Retrospective Analysis

Koksal B., Yildirim H. C., Guven D. C., Kose F., Koymen G., Ozdemir O., et al.
JOURNAL OF CLINICAL MEDICINE , vol.15, no.4, pp.1-14, 2026 (SCI-Expanded, Scopus) Creative Commons License

34. Prognostic Factors and Real-World Outcomes in Patients Aged 65 Years and Older with Stage II and III Colon Cancer

Birsin Z., Cebeci S., Jeral S., Aliyev V., Demirci N. S., Alan Ö.
Eurasian Journal of Medical Investigation , vol.9, no.4, pp.1-13, 2026 (TRDizin) Creative Commons License

35. Bevacizumab combined with irinotecan or temozolomide in recurrent glioblastoma: a Turkish Oncology Group (TOG) study

Akbas S., Alan Ö., Yildiz O., Karakurt M., Yildirim E. C., Colak R., et al.
JOURNAL OF NEURO-ONCOLOGY , vol.176, no.2, pp.1-9, 2026 (SCI-Expanded, Scopus)

36. Long-Term Oncological Outcomes for Locally Advanced Rectal Cancer Patients with Pathological Complete Response After Neoadjuvant Chemoradiotherapy: A Turkish Oncology Group Study

Uysal M., Saglam S., Beypınar İ., Saglam E. K., Mammadov E., Ocak B., et al.
CANCER INVESTIGATION , vol.44, no.2, pp.127-135, 2026 (SCI-Expanded, Scopus) Creative Commons License

37. Stage II colon cancer: does ChatGPT recommend more intensive adjuvant therapy? A comparison with MDT decisions.

Birsin Z., Jeral S., Cebeci S., Çerme E., Aliyev V., Günaltılı M., et al.
Future oncology (London, England) , pp.1-8, 2025 (SCI-Expanded, Scopus)

38. Chronic kidney disease and denosumab in metastatic bone disease: A multicenter Turkish cohort study on severe hypocalcemia, skeletal events, and survival

Ellez H. İ., Semiz H. S., Ekinci F., Erdoğan A. P., Kuş F., Karataş F., et al.
JOURNAL OF BONE ONCOLOGY , vol.55, pp.1-7, 2025 (SCI-Expanded, Scopus) Creative Commons License

39. Independent Prognostic Role of Postoperative Carcinoembryonic Antigen in Stage II Colon Cancer

Birsin Z., Aliyev V., Jeral N. S., Cebeci S., Abbasov H., Demirci N. S., et al.
Cerrahpaşa Medical Journal , vol.2025, no.49, pp.1-8, 2025 (TRDizin) Creative Commons License

40. Durvalumab-Based First-Line Chemoimmunotherapy in Advanced Biliary Tract Cancer: Real-World Outcomes and Prognostic Factors—A Turkish Oncology Group Study

Efil S. C., Kus F., Koylu B., Durukan B. M., Bayram S., Guzel H. G., et al.
CANCERS , vol.18, no.1, pp.1-21, 2025 (SCI-Expanded, Scopus) Creative Commons License

41. Thrombotic Microangiopathy Associated with Etoposide in Metastatic Lung Cancer: Diagnostic and Therapeutic Challenges

Güzel S. S., Çakan Z. K., Karalı O., Çavlı H. B., Demirci N. S., Alan Ö.
Journal of oncological sciences , vol.11, no.2, pp.1-6, 2025 (Scopus, TRDizin) Creative Commons License

42. Prognostic impact of hand-foot skin reaction in regorafenib-treated adult-type diffuse gliomas: A multicenter Turkish Oncology Group study.

Efil S. C., Bilgin B., Bilgetekin I., Helvaci K., Sakalar T., Nayir E., et al.
Scientific reports , vol.15, no.1, pp.36175, 2025 (SCI-Expanded, Scopus)

43. Inflammatory and Nutritional Markers Predicting Pathological Complete Response to Neoadjuvant Therapy in HER2-Positive Breast Cancer: A Multicenter Real-World Study

Birsin Z., Nazli I., Alkan O., ODABAŞI BÜKÜN H., Gunaltili M., Cerme E., et al.
JOURNAL OF CLINICAL MEDICINE , vol.14, no.20, 2025 (SCI-Expanded, Scopus) Creative Commons License Sustainable Development

44. Immune Checkpoint Inhibitor Associated Kidney Transplant Rejection: A Real World Pharmacovigilance Analysis Using the FAERS Database

Mütiş Alan A., Alan Ö.
The Eurasian Journal of Medical Investigation , vol.9, no.3, pp.176-181, 2025 (TRDizin) Creative Commons License

45. Prognostic impact of pan-immune-inflammation value and prognostic nutritional index in metastatic colorectal cancer patients treated with regorafenib

Yıldırım S., Alan Ö., Yıldız H. Ş., Doğan A., Ay Ersoy S., Odabaş H.
THE EUROPEAN RESEARCH JOURNAL , vol.1, no.11, pp.1-11, 2025 (TRDizin) Creative Commons License

46. Impact of Blood Type on Treatment Response and Survival in HER2-Negative Metastatic Gastric Cancer

Yıldırım S., Alan Ö., Türkoğlu E., Sariyar Busery N., Doğan A., Akdağ G., et al.
Cerrahpaşa Medical Journal , vol.49, no.0042, pp.1-6, 2025 (TRDizin) Creative Commons License

47. Palbociclib in liposarcoma: real-world multicenter data from the Turkish Oncology Group (TOG).

Kus F., Yildirim H. C., Bayram D., Bal O., Sahin G., Ugrakli M., et al.
Journal of chemotherapy (Florence, Italy) , pp.1-9, 2025 (SCI-Expanded, Scopus)

48. Comparative Efficacy and Cost-Effectiveness of Denosumab Versus Zoledronic Acid in Cancer Patients with Bone Metastases

Aliyev V., Guliyev M., Gunaltili M., Fidan M. C., Cerme E., Abbasov H., et al.
JOURNAL OF CLINICAL MEDICINE , vol.14, no.18, 2025 (SCI-Expanded, Scopus) Creative Commons License Sustainable Development

49. Evaluating the Prognostic Role of Pan-Immune-Inflammation Value in Patients with Advanced Non-Small Cell Lung Cancer Treated with Nivolumab

Guliyev M., Alan Ö., Fidan M. C., Abbasov H., Cebeci S., Aliyev V., et al.
Cerrahpaşa Medical Journal , vol.49, no.1, pp.1-9, 2025 (TRDizin) Creative Commons License

50. Is Body Mass Index a Prognostic Factor in Metastatic HER2-Positive Breast Cancer? A Real-World Multicenter Study

Birsin Z., Odabaşı Bükün H., Nazlı İ., Alkan O., Günaltılı M., Çerme E., et al.
MEDICINA (KAUNAS, LITHUANIA) , vol.61, no.9, pp.1-13, 2025 (SCI-Expanded, Scopus)

51. Low Skeletal Muscle Index as a Predictor of Pathological Complete Response in HER-2 Positive and Triple-Negative Breast Cancer

Günaltılı M., Guliyev M., Fidan M. C., Birsin Z., Çerme E., Aliyev V., et al.
MEDICINA (KAUNAS, LITHUANIA) , vol.61, no.9, pp.1-13, 2025 (SCI-Expanded, Scopus) Creative Commons License

52. Real-World Outcomes in BRAF-Mutant Non-small Cell Lung Cancer: A Multicenter Analysis from the Turkish Oncology Group

Telli T. A., Tatlı A. M., Alan Ö., Keskin G. Y., Karadurmuş N., Karakaya S., et al.
CLINICAL LUNG CANCER , vol.1, no.1, pp.1-30, 2025 (SCI-Expanded, Scopus)

53. The Impact of Low HER2 expression on clinicopathological features and clinical outcomes in patients with metastatic gastric cancer

Guliyev M., Safarov S., Günaltılı M., Fidan M. C., Çerme E., Alkan Şen G., et al.
CLINICS AND RESEARCH IN HEPATOLOGY AND GASTROENTEROLOGY , vol.1, pp.1-22, 2025 (SCI-Expanded, Scopus)

54. Prognostic Role of Inflammatory and Nutritional Indices in NSCLC Patients Treated with Immune Checkpoint Inhibitors: Retrospective, Multicenter, Turkish Oncology Group Study of Overall and Elderly Populations

Alan Ö., Akin Telli T., Akbaş S., Işık S., Çavdar E., Karaboyun K., et al.
MEDICINA (KAUNAS, LITHUANIA) , vol.61, no.7, pp.1-13, 2025 (SCI-Expanded, Scopus) Creative Commons License

55. First-Line Chemotherapy Versus CDK4/6 Inhibitors in HR-Positive, HER2-Negative Breast Cancer with Liver Metastases: A Multicenter Real-World Data

Fidan M. C., Öztürk A. E., Aydın O., Akdağ G., Türkoğlu E., Çolak R., et al.
JOURNAL OF CLINICAL MEDICINE , vol.14, no.13, pp.1-18, 2025 (SCI-Expanded, Scopus) Creative Commons License

56. The impact of carboplatin on pathologic complete response and survival based on HER2 low and HER2 zero status in triple negative breast cancer patients receiving neoadjuvant chemotherapy: a multicenter real-world analysis.

Yıldırım S., Başoğlu T., Doğan A., Akdağ G., Kınıkoğlu O., Topal A., et al.
BMC cancer , vol.25, no.1, pp.833, 2025 (SCI-Expanded, Scopus)

57. Efficacy of Second-Line Treatments After Atezolizumab and Bevacizumab in Advanced Hepatocellular Carcinoma and Related Prognostic Factors: A Multicenter Study by the Turkish Oncology Group (TOG)

Majidova N., Yaslıkaya Ş., Mıldanoglu M. M., Coskun A., Ercan Uzundal D., Sahin T. K., et al.
TURKISH JOURNAL OF GASTROENTEROLOGY , vol.1, no.1, pp.1-9, 2025 (SCI-Expanded, Scopus, TRDizin) Creative Commons License

58. Prognostic Significance of Inflammatory and Nutritional Biomarkers in Patients with Metastatic Gastric Cancer

Guliyev M., Alan Ö., Safarov S., Alkan Şen G., Günaltılı M., Fidan M. C., et al.
Journal of oncological sciences , vol.11, no.1, pp.14-21, 2025 (TRDizin) Creative Commons License

59. Neurotoxicity in the Era of Immune Checkpoint Inhibitors: A Case-Based Approach

Alan Ö., Altıntaş Y. E., Bayram Kuvvet B., Duman A., Bülbül M. C., Çeleb O., et al.
Journal of oncological sciences , vol.11, no.1, pp.50-54, 2025 (TRDizin) Creative Commons License

60. Evaluation of Dose Reduction Factors and Impact on Progression-Free Survival in Patients Treated with CDK 4/6 Inhibitors.

Güren A. K., Guliyev M., Alan Ö., Çadırci K., Belevi İ. N., Gültürk İ., et al.
Journal of clinical medicine , vol.14, no.4, 2025 (SCI-Expanded, Scopus) Creative Commons License

61. The Impact of Progesterone Receptor Status on Survival Outcomes in Metastatic Breast Cancer Patients Treated with First-Line CDK4/6 Inhibitors

Guliyev M., Güren A. K., Özge E., Çolak R., Majidova N., Alkan Şen G., et al.
CANCERS , vol.17, no.4, 2025 (SCI-Expanded, Scopus) Creative Commons License

62. Prognostic factors and outcomes of adjuvant and first-line metastatic treatments in melanoma a Turkish oncology group study.

Majidova N., Arak H., Ozalp F. R., Bas O., Koker G. O., Ozmarasalı E. B., et al.
Scientific reports , vol.15, no.1, pp.3200, 2025 (SCI-Expanded, Scopus)

63. Immunotherapy-related secondary hemophagocytosis in a glioblastoma patient: response to cytokine-directed therapy

Alan Ö., Bulbul M. C., Enlice M. A., Mandel N. M.
IMMUNOTHERAPY , vol.17, no.1, pp.11-17, 2025 (SCI-Expanded, Scopus)

64. The role of laboratory indices on treatment response and survival in breast cancer receiving neoadjuvant chemotherapy

Yildirim S., Dogan A., Akdag G., Yüksel Yasar Z., Bal H., Kinikoglu O., et al.
Scientific Reports , vol.14, no.1, 2024 (SCI-Expanded, Scopus)

65. Nivolumab, Ramucirumab and Paclitaxel Combination as Second Line Therapy for Advanced Stage Gastric Cancer

Akbaş S., Alan Ö., Bayram Kuvvet B., Laçin Ş., Köylü B., Selçukbiricik F.
EURASIAN JOURNAL OF MEDICINE AND ONCOLOGY , vol.8, no.4, pp.488-495, 2024 (ESCI, TRDizin) Creative Commons License

66. Obesity Is an Independent Prognostic Factor That Reduced Pathological Complete Response in Operable Breast Cancer Patients.

Guliyev M., Alan Ö., Günaltılı M., Safarov S., Fidan M. C., Alkan Şen G., et al.
Medicina (Kaunas, Lithuania) , vol.60, no.12, 2024 (SCI-Expanded, Scopus) Creative Commons License

67. Neoadjuvant Chemotherapy Shortens the cfDNA Telomere Length in Breast Cancer Patients.

Peker Eyüboğlu İ., Koca S., Çelik B., Güllü Amuran G., Uğurlu M. Ü., Alan Ö., et al.
International journal of breast cancer , vol.2024, pp.6117394, 2024 (ESCI)

68. Evaluating the Effectiveness of Nivolumab in Metastatic Lung Cancer Among Patients Aged 65 and Older

Isik D., Alan Ö., Akdağ G., Yildirim S., Kınıkoğlu O., Altintas Y. E., et al.
Journal of Clinical Medicine , vol.13, no.20, 2024 (SCI-Expanded, Scopus)

69. Prognostic value of psoas muscle index in metastatic renal cell carcinoma patients treated with anti-VEGF therapy.

Arıkan R., Demircioğlu Ö., Özgüven S., Demircan N. C., Alan Ö., Telli T. A., et al.
Indian journal of cancer , vol.61, no.4, pp.789-796, 2024 (SCI-Expanded, Scopus)

70. Real-world evaluation of nivolumab in patients with non-nasopharyngeal recurrent or metastatic head and neck cancer: a retrospective multi-center study by the Turkish Oncology Group (TOG)

Akyildiz A., GÜVEN D. C., Koksal B., KARAOĞLAN B. B., Kivrak D., Ismayilov R., et al.
EUROPEAN ARCHIVES OF OTO-RHINO-LARYNGOLOGY , vol.281, no.9, pp.4991-4999, 2024 (SCI-Expanded, Scopus) Creative Commons License

71. Prognostic Impact and Clinical Features of Spread through Air Spaces in Operated Lung Cancer: Real-World Analysis

Yildirim S., Alan Ö., Yuksel Yasar Z., Kaya T., Akdag G., Kinikoglu O., et al.
Medicina (Lithuania) , vol.60, no.8, 2024 (SCI-Expanded, Scopus)

72. Efficacy and Safety of Ixabepilone in Metastatic Breast Cancer After Multiple Treatments: Analysis Based on Real-World Data

Akdağ G., Alan Ö., Doğan A., Yildirim S., Kinikoğlu O., Majidova N., et al.
Journal of oncological sciences , vol.10, no.2, pp.89-96, 2024 (TRDizin)

73. A propensity score-matched comparison of neoadjuvant chemoradiotherapy with cisplatin-5FU and carboplatin–paclitaxel in locally advanced esophageal squamous cell carcinoma: A Turkish oncology group study

Gürler F., Tay F., Sucuoğlu İşleyen Z., Yerlikaya T., Hendem E., Esen S. A., et al.
Cancer Medicine , vol.13, no.14, 2024 (SCI-Expanded, Scopus)

74. Real-world evaluation of nivolumab in patients with non-nasopharyngeal recurrent or metastatic head and neck cancer: A retrospective multi-center study by the Turkish Oncology Group (TOG).

Akyildiz A., Guven D. C., Koksal B., Karaoglan B. B., Salim D. K., Sutcuoglu O., et al.
JOURNAL OF CLINICAL ONCOLOGY , no.16, 2024 (SCI-Expanded, Scopus)

75. Neoadjuvant Chemotherapy and Pathologic Complete Response in HR+/HER2− Breast Cancer: Impact of Tumor Ki67 and ER Status

Akdag G., Yildirim S., Dogan A., Yasar Z. Y., Bal H., Kinikoglu O., et al.
Chemotherapy , vol.69, no.3, pp.141-149, 2024 (SCI-Expanded, Scopus)

76. Prognostic scores in pulmonary large cell neuroendocrine carcinoma: A retrospective cohort study

Akdag G., Alan Ö., Dogan A., Yildirim S., Kinikoglu O., Batu A., et al.
Heliyon , vol.10, no.3, 2024 (SCI-Expanded, Scopus)

77. The real-world outcomes of Lutetium-177 PSMA-617 radioligand therapy in metastatic castration-resistant prostate cancer: Turkish Oncology Group multicenter study

Almuradova E., Seyyar M., Arak H., Tamer F., Kefeli U., Koca S., et al.
International Journal of Cancer , vol.154, no.4, pp.692-700, 2024 (SCI-Expanded, Scopus)

78. Correlation between plasma ccfDNA, mtDNA changes, CTCs, and epithelial-mesenchymal transition in breast cancer patients undergoing NACT

Çelik B., PEKER EYÜBOĞLU İ., Koca S., Ümit Uğurlu M., Alan Ö., GÜLLÜ AMURAN G., et al.
Turkish Journal of Medical Sciences , vol.54, no.4, pp.652-665, 2024 (SCI-Expanded, Scopus, TRDizin) Creative Commons License

79. PROPSEA, safety evaluation of palbociclib and ribociclib in older patients with breast cancer: A prospective real-world TOG study

Avci O., Iriagac Y., Cavdar E., Karaboyun K., Araz M., Sakalar T., et al.
JOURNAL OF GERIATRIC ONCOLOGY , vol.14, no.8, 2023 (SCI-Expanded, Scopus)

80. Efficacy of Capecitabine and Temozolomide Regimen in Neuroendocrine Tumors: Data From the Turkish Oncology Group.

Ünal Ç., AZİZY A., KARABULUT S., TAŞTEKİN D., AKYILDIZ A., YAŞAR S., et al.
The oncologist , vol.28, no.10, pp.875-884, 2023 (SCI-Expanded, Scopus) Creative Commons License

81. Outcomes of surveillance versus adjuvant treatment for patients with stage-I seminoma: a single-center experience

Akdag G., Alan Ö., Dogan A., Yuksel Z., Yildirim S., Kinikoglu O., et al.
World Journal of Urology , vol.41, no.8, pp.2201-2207, 2023 (SCI-Expanded, Scopus)

82. Major and minor salivary gland cancers: A multicenter retrospective study.

Hacioglu M. B., ERDOĞAN B., Bardakcı M., Algın E., Gulbagcı B., Hacibekiroglu I., et al.
Head & neck , vol.45, no.7, pp.1643-1653, 2023 (SCI-Expanded, Scopus)

83. The Prognostic and Predictive role of DR70 immunoassay in Patients with Advanced (Metastatic) Breast Cancer

KOCA S., BABACAN N. A., ÖKTEN İ. N., TELLİ T. A., ALAN Ö., Aktas B., et al.
Eurasian Journal of Medical Investigation , vol.7, no.2, pp.170-174, 2023 (TRDizin)

84. Evaluation of the effectiveness of drug-eluting transarterial chemoebolization in hepatocellular carcinoma

Alan A. M., Alan Ö., Asadov R., DEMİRTAŞ C. Ö., KANİ H. T., Yumuk P. F., et al.
Hepatology Forum , vol.4, no.2, pp.53-60, 2023 (Scopus)

85. Age-adjusted Charlson Comorbidity Index is a valuable prognostic tool in operable soft tissue sarcoma of trunk and extremities

Telli T. A., Alan Ö., Demircan N. C., Sariyar N., Arikan R., Basoglu T., et al.
Orthopaedics and Traumatology: Surgery and Research , vol.109, no.3, 2023 (SCI-Expanded, Scopus)

86. Real-life experience of patients with sarcomatoid renal cell carcinoma: a multicenter retrospective study

Almuradova E., Basoglu T., Nayir E., Bayram E., Paydas S., Gokmen I., et al.
Neoplasma , vol.70, no.1, pp.158-165, 2023 (SCI-Expanded, Scopus) Creative Commons License

87. Real-life comparison of afatinib and erlotinib in non-small cell lung cancer with rare EGFR exon 18 and exon 20 mutations: a Turkish Oncology Group (TOG) study

Gursoy P., Tatli A. M., Erdem D., Goker E., Celik E., Demirci N. S., et al.
Journal of Cancer Research and Clinical Oncology , vol.149, no.2, pp.865-875, 2023 (SCI-Expanded, Scopus) Creative Commons License

88. Real life experience of patients with locally advanced gastric and gastroesophageal junction adenocarcinoma treated with neoadjuvant chemotherapy: a Turkish oncology group study

Başoğlu T., Sakin A., Erol C., Özden E., Çabuk D., Çılbır E., et al.
Journal of Chemotherapy , vol.35, no.2, pp.142-149, 2023 (SCI-Expanded, Scopus) Creative Commons License

89. Assessing the Clinical Impact of Lutetium-177 DOTATATE Peptide Receptor Radionuclide Therapy (PRRT) on Metastatic Neuroendocrine Tumors: A Multicenter Real-World Data from Türkiye

Unal C., Selcuk N. A., Biricik F. S., Alan Ö., Ordu C., Selvi O., et al.
Eurasian Journal of Medicine and Oncology , vol.7, no.3, pp.232-242, 2023 (ESCI, Scopus, TRDizin)

90. Clinical and inflammation marker features of cancer patients with COVID-19: data of Istanbul, Turkey multicenter cancer patients (2020–2022)

Ünal Ç., Tunçer G., Çopur B., Pilanci K. N., Okutur K. S., Yararbaş K., et al.
Current Medical Research and Opinion , vol.39, no.7, pp.987-996, 2023 (SCI-Expanded, Scopus)

91. Role of baseline 68Ga-PSMA PET/CT-derived whole-body volumetric parameters in predicting survival outcomes of metastatic castration-resistant prostate cancer patients receiving first-line treatment

Telli T. A., ÖZGÜVEN S., ALAN Ö., Filizoglu N., ÖZTÜRK M. S., Sariyar N., et al.
ANNALS OF NUCLEAR MEDICINE , vol.36, no.11, pp.964-975, 2022 (SCI-Expanded, Scopus) Sustainable Development

92. Prognostic factors of perioperative FLOT regimen in operable gastric and gastroesophageal junction tumors: real-life data (Turkish Oncology Group)

Erol C., Sakin A., Başoglu T., Özden E., ÇABUK D., Doğan M., et al.
Turkish Journal of Medical Sciences , vol.52, no.4, pp.1022-1032, 2022 (SCI-Expanded, Scopus, TRDizin) Creative Commons License

93. Real-world assessment of quality-of-life in patients with breast cancer treated with adjuvant endocrine therapy

Telli T. A., ÖZTÜRK M. S., Alan Ö., Hasanov R., KÖSTEK O., Arikan R., et al.
Future Oncology , vol.18, no.22, pp.2425-2439, 2022 (SCI-Expanded, Scopus)

94. The Prognostic and Predictive Value of DR-70 Immunoassay, A Novel Fibrin-Associated Biomarker, in Patients with Advanced Gastrointestinal Cancers

ÇETİN M., BABACAN N. A., ALAN Ö., OZTURK M. A., HASANOV R., KOCA S., et al.
Namık Kemal Tıp Dergisi , vol.10, no.1, pp.74-79, 2022 (TRDizin)

95. Impact of Skeletal Muscle Measurements by Chest Computed Tomography on Survival and Postoperative Complications in Patients with Soft Tissue Sarcoma

Telli T. A., BUĞDAYCI O., Alan Ö., Sariyar N., Isik S., Arikan R., et al.
Nutrition and Cancer , vol.74, no.7, pp.2499-2507, 2022 (SCI-Expanded, Scopus)

96. Immunogenicity and safety of the CoronaVac vaccine in patients undergoing treatment for breast and lung cancer

Yakup I., Eyyup C., Kubilay K., Okan A., Ozkan A., Halil T., et al.
Bratislava Medical Journal , vol.123, no.6, pp.401-407, 2022 (SCI-Expanded, Scopus) Creative Commons License

97. Association of Pre-treatment Sarcopenia with Side Effects and Prognosis in Non-small Cell Lung Cancer Patients Receiving Erlotinib

Demircan N. C., Engür C. Ö., Akin Telli T., Başoğlu T., Arikan R., Yaşar A., et al.
Turk Onkoloji Dergisi , vol.37, no.4, pp.379-387, 2022 (ESCI, Scopus, TRDizin) Creative Commons License

98. The effect of preoperative prognostic nutritional index on outcome in glioblastoma multiforme patients

Oyman A., Işık S., Eröz S., Özçelik M., Cil I., Alan Ö., et al.
The Journal of Surgery and Medicine (JOSAM , vol.6, no.2, pp.177-180, 2022 (Peer-Reviewed Journal) Creative Commons License

99. Impact of prognostic nutritional index on survival in recurrent glioblastoma Impacto de Prognostic Nutritional Index en la supervivencia de los glioblastomas recurrentes

Alan Ö., Telli T. A., Basoğlu T., Arikan R., Demircan N. C., Ercelep O., et al.
Neurocirugia , vol.33, no.1, pp.15-21, 2022 (SCI-Expanded, Scopus)

100. First-line treatment of patients with HER2-positive metastatic gastric and gastroesophageal junction cancer

Esen S. A., Ergun Y., Erol C., Arikan R., Er M. M., Atci M. M., et al.
Bosnian Journal of Basic Medical Sciences , vol.22, no.5, pp.818-825, 2022 (SCI-Expanded, Scopus)

101. Real-life comparison of the afatinib and first-generation tyrosine kinase inhibitors in nonsmall cell lung cancer harboring EGFR exon 19 deletion: a Turk Oncology Group (TOG) study

Bilgin B., Sendur M. A. N., Yucel S., Celik E., Ozyukseler D. T., Ayhan M., et al.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY , vol.147, no.7, pp.2145-2152, 2021 (SCI-Expanded, Scopus) Sustainable Development

102. Differences in PET/CT standardized uptake values involvement and survival compared to histologic subtypes of lung adenocarcinoma

Ercelep O., Alan Ö., Telli T. A., Tuylu T. B., Arıkan R., Demircan N. C., et al.
Tumori , vol.107, no.3, pp.231-237, 2021 (SCI-Expanded, Scopus)

103. The role of adjuvant chemotherapy in resected stage I non - small cell lung cancer: A Turkish Oncology Group Study

AK N., ÖZKAN B., Yenigun M. B., Yilmazbayhan D., Toker A., Ferhatoglu F., et al.
JOURNAL OF BUON , vol.26, no.3, pp.819-829, 2021 (SCI-Expanded, Scopus) Sustainable Development

104. Preoperative Prognostic Nutritional Index is a Strong Predictorof Survival in Patients with Localized Soft Tissue Sarcoma

TELLİ T. A., SARIYER N., ALAN Ö., DEMİRCAN N. C., IŞIK S., ARIKAN R., et al.
Eurasian Journal of Medical Investigation , vol.5, no.2, pp.256-262, 2021 (TRDizin)

105. Clinicopathologic and Radiologic Characteristics of Pleomorphic Lobular Breast Cancer

ARIKAN R., TELLİ T. A., ALAN Ö., DEMİRCAN N. C., BAŞOĞLU T., ERCELEP Ö., et al.
Eurasian Journal of Medical Investigation , vol.5, no.1, pp.148-152, 2021 (TRDizin) Creative Commons License

106. Prognostic factors in progressive high-grade glial tumors treated with systemic approach: A single center experience

Alan Ö., Telli T. A., Tuylu T. B., Arikan R., Demircan N. C., Ercelep O., et al.
Journal of Oncology Pharmacy Practice , vol.27, no.2, pp.329-339, 2021 (SCI-Expanded, Scopus)

107. Clinicopathological features, treatment outcomes, and prognostic factors in adrenocortical carcinoma: A single-center experience

Demircan N. C., Akin Telli T., Başoğlu T., Arikan R., Yaşar A., Çelebi A., et al.
Journal of Oncological Science , vol.7, no.3, pp.133-138, 2021 (Scopus, TRDizin) Creative Commons License

108. Modified Glasgow Prognostic Score, Prognostic Nutritional Index and ECOG Performance Score Predicts Survival Better than Sarcopenia, Cachexia and Some Inflammatory Indices in Metastatic Gastric Cancer

Demirelli B., Babacan N. A., Ercelep Ö., Öztürk M. A., Kaya S., Tanrıkulu E., et al.
Nutrition and Cancer , vol.73, no.2, pp.230-238, 2021 (SCI-Expanded, Scopus)

109. Efficacy and Safety of Trastuzumab Emtansine in Her2 Positive Metastatic Breast Cancer: Real-World Experience

Bahceci A., PAYDAŞ S., Ak N., Ferhatoglu F., Saip P. M., SEYDAOĞLU G., et al.
CANCER INVESTIGATION , vol.39, pp.473-481, 2021 (SCI-Expanded, Scopus) Sustainable Development

110. Comparison of three different chemotherapy regimens for concomitant chemoradiotherapy in locally advanced non-small cell lung cancer

Akdeniz N., Küçüköner M., Kaplan M. A., Urakçı Z., Karhan O., Sezgin Y., et al.
International Journal of Clinical Oncology , vol.25, no.12, pp.2015-2024, 2020 (SCI-Expanded, Scopus)

111. Prognostic Factors in Operated Early Stage Lung Cancer Patients- Retrospective Single Center Data

ALAN Ö., ERCELEP Ö., TELLİ T. A., TANRIKULU E. Ş., HASANOV R., BASOGLU T., et al.
Namık Kemal Tıp Dergisi , vol.8, no.3, pp.376-382, 2020 (TRDizin)

112. Efficacy of Palbociclib and Endocrine Treatment in Heavily Pretreated Hormone Receptor-positive/HER2-negative Advanced Breast Cancer: Retrospective Multicenter Trial

DEMİR A., DEMİR G., ER Ö., ERALP Y., ULUÇ B. O., UYSAL Ö. S., et al.
Balkan Medical Journal , vol.37, no.2, pp.104-107, 2020 (SCI-Expanded, Scopus, TRDizin)

113. Worse patient–physician relationship is associated with more fear of cancer recurrence (Deimos Study): A study of the Palliative Care Working Committee of the Turkish Oncology Group (TOG)

Alkan A., Yaşar A., Zeynep Gülsüm G., Gürbüz M., Başoğlu T., Sezgin Göksu S., et al.
European Journal of Cancer Care , vol.29, no.6, 2020 (SCI-Expanded, SSCI, Scopus)

114. VEGF-VEGFR pathway seems to be the best target in hepatic epithelioid hemangioendothelioma: A case series with review of the literature

Telli T. A., Okten I. N., Tuylu T. B., Demircan N. C., Arikan R., Alan Ö., et al.
Current Problems in Cancer , vol.44, no.5, 2020 (SCI-Expanded, Scopus)

115. Is insulin resistance a predictor for complete response in breast cancer patients who underwent neoadjuvant treatment?

Alan Ö., Akin Telli T., Aktas B., Koca S., Ökten I. N., Hasanov R., et al.
World Journal of Surgical Oncology , vol.18, no.1, 2020 (SCI-Expanded, Scopus) Creative Commons License

116. Comparison of Seventh and Eighth Editions of TNM Staging Classification and Evaluation of Survivals in Operated Non-Small Cell Lung Carcinomas: Single Center Experience

ERCELEP Ö., ALAN Ö., TELLİ T. A., TÜYLÜ T. B., ARIKAN R., DEMİRCAN N. C., et al.
Eurasian Journal of Medical Investigation , vol.4, no.2, pp.243-246, 2020 (TRDizin)

117. The Relationship Between the Prognostic Nutritional Index and Overall Survival in Elderly Patients with Epithelial Ovarian Cancer

DEMİR A., ALAN Ö., KOCA S., SÜRMELİ H.
Eurasian Journal of Medical Investigation , vol.4, no.2, pp.269-273, 2020 (TRDizin)

118. Prognostic value of modified Glasgow prognostic score in recurrent high-grade glial tumors treated with systemic treatment

Alan Ö., Telli T. A., Basoğlu T., Arikan R., Demircan N. C., Ercelep O., et al.
Clinical Neurology and Neurosurgery , vol.196, 2020 (SCI-Expanded, Scopus)

119. Response Assessment With Molecular Characterization of Circulating Tumor Cells and Plasma MicroRNA Profiling in Patients With Locally Advanced Breast Cancer During Neoadjuvant Chemotherapy

AKKİPRİK M., Koca S., UĞURLU M. Ü., Ekren R., PEKER EYÜBOĞLU İ., Alan Ö., et al.
Clinical Breast Cancer , vol.20, no.4, pp.332, 2020 (SCI-Expanded, Scopus)

120. Impact of the Charlson Comorbidity Index on dose-limiting toxicity and survival in locally advanced and metastatic renal cell carcinoma patients treated with first-line sunitinib or pazopanib

Demircan N. C., Alan Ö., Başoğlu Tüylü T., Akın Telli T., Arıkan R., Çiçek F. C., et al.
Journal of Oncology Pharmacy Practice , vol.26, no.5, pp.1147-1155, 2020 (SCI-Expanded, Scopus)

121. A case of spontaneous tumor lysis syndrome in extensive-stage small-cell lung cancer: A rare oncologic emergency

Alan A., Alan Ö.
TURKISH JOURNAL OF EMERGENCY MEDICINE , vol.20, no.3, pp.142-145, 2020 (ESCI, Scopus)

122. A rare case of primary rectal choriocarcinoma and review of the literature

Telli T. A., Demircan N. C., Alan Ö., Tuylu T. B., Arikan R., Ercelep O., et al.
Journal of Oncology Pharmacy Practice , vol.26, no.4, pp.989-994, 2020 (SCI-Expanded, Scopus)

123. How long should we continue crizotinib in ALK translocation-positive inflammatory myofibroblastic tumors? Long-term complete response with crizotinib and review of the literature

Alan Ö., Kuzhan O., Koca S., Telli T. A., Basoglu T., Ercelep O., et al.
Journal of Oncology Pharmacy Practice , vol.26, no.4, pp.1011-1018, 2020 (SCI-Expanded, Scopus)

124. Early PSA response to antiandrogen therapy in metastatic castration-resistant prostate carcinoma patients: A predictive marker for progression-free survival?

Atakan D., Ozkan A., Guve M. A., Sinan K.
Journal of B.U.ON. : official journal of the Balkan Union of Oncology , vol.25, no.3, pp.1625-1630, 2020 (SCI-Expanded, Scopus)

125. Predictive Values of Systemic Inflammation Index in Prognosis of Patients with Laryngeal Cancer

Demir A., Alan Ö., Surmeli M.
Eurasian Journal of Medicine and Oncology , vol.4, no.1, pp.49-53, 2020 (ESCI, Scopus, TRDizin)

126. Smokers having activating EGFR mutant non-small cell lung cancer might benefit from EGFR-TKI treatment – single-center experience

Ercelep Ö., Akin Telli T., Alan Ö., Hasanov R., Tanrikulu Şimşek E., Akgül Babacan N., et al.
Turk Onkoloji Dergisi , vol.35, no.3, pp.334-339, 2020 (ESCI, Scopus, TRDizin) Creative Commons License

127. Is Laboratory Prognostic Index a Valuable Prognostic Index for Malignant Pleural Mesothelioma?

Tuylu T. B., Demircan N. C., Arikan R., Telli T. A., ALAN Ö., Ercelep O., et al.
JOURNAL OF THORACIC ONCOLOGY , no.10, 2019 (SCI-Expanded, Scopus)

128. The Role Adjuvant Chemotherapy in Resected Stage 1 NSCLC with High Risk Factors: A Turkish Oncology Group Study

ERALP Y., AK N., Yilmazbayhan D., ÖZKAN B., FERHATOĞLU F., Demirkazik A., et al.
JOURNAL OF THORACIC ONCOLOGY , no.10, 2019 (SCI-Expanded, Scopus)

129. A case of primary squamous cell carcinoma of the breast with pathologic complete response after neoadjuvant chemotherapy

Alan Ö., Telli T. A., Ercelep O., Hasanov R., Simsek E. T., Mutis A., et al.
CURRENT PROBLEMS IN CANCER , vol.43, no.4, pp.308-311, 2019 (SCI-Expanded, Scopus)

130. Assessment of survival and prognostic factors in metastatic colorectal cancer patients treated with first-line bevacizumab-based therapy.

Demircan N., Dane F., Ozturk M. A., Babacan N. A., Besiroglu M., Kaya S., et al.
Journal of B.U.ON. : official journal of the Balkan Union of Oncology , vol.24, no.4, pp.1494-1500, 2019 (SCI-Expanded, Scopus)

131. Effect of PET/CT standardized uptake values on complete response to treatment before definitive chemoradiotherapy in stage III non-small cell lung cancer

Ercelep O., ALAN Ö., Sahin D., Telli T. A., Salva H., Tuylu T. B., et al.
CLINICAL & TRANSLATIONAL ONCOLOGY , vol.21, no.4, pp.499-504, 2019 (SCI-Expanded, Scopus) Sustainable Development

132. MEAN PLATELET VOLUME (MPV) FOR PREDICTING PROGNOSIS OF RECTUM CANCER AFTER NEOADJUVANT TREATMENT

DEMİR A., ALAN Ö.
Namık Kemal Tıp Dergisi , vol.7, no.3, pp.279-286, 2019 (TRDizin)

133. Tumor budding for predicting prognosis of resected rectum cancer after neoadjuvant treatment

Demir A., Alan Ö., Oruc E.
World Journal of Surgical Oncology , vol.17, no.1, 2019 (SCI-Expanded, Scopus)

134. Is Preoperative SUV(Max) of Primary Tumor a Predictor of Relapse for Operable Non-Small Cell Lung Cancer?

ALAN Ö., Ercelep O., Telli T. A., Tuylu T. B., ÖNEŞ T., BOZKURTLAR E., et al.
JOURNAL OF THORACIC ONCOLOGY , no.10, 2018 (SCI-Expanded, Scopus)

135. Chordoma: A case series and review of the literature

Alan Ö., Akin Telli T., Ercelep O., Tanrikulu Simsek E., Basoglu Tuylu T., Mutis A., et al.
Journal of Medical Case Reports , vol.12, no.1, 2018 (Scopus)

136. Prognostic factors in early stage lung cancer patients: Retrospective single center data.

ALAN Ö., Ercelep O., Telli T. A., Hasanov R., Tuylu T. B., Simsek E. T., et al.
JOURNAL OF CLINICAL ONCOLOGY , no.15, 2018 (SCI-Expanded, Scopus)

137. Smokers Having Activating EGFR Mutant Non-Small Cell Lung Cancer Might Benefit from EGFR-TKI Treatment - Single Center Experience

Ercelep O., Telli T., ALAN Ö., Hasanov R., Simsek E., Halil S., et al.
JOURNAL OF THORACIC ONCOLOGY , no.11, 2017 (SCI-Expanded, Scopus)

138. A Retrospective Review of Small Cell Lung Cancer (SCLC) Patients Treated at Marmara University Hospital

Eris A., ÖZTÜRK M., Dane F., BOZKURTLAR E., KOCAKAYA D., ALAN Ö., et al.
JOURNAL OF THORACIC ONCOLOGY , no.11, 2017 (SCI-Expanded, Scopus)

139. Changes in 18F-FDG-PET/CT tumor metabolism are not consistent with pathologic complete response in hormone-positive breast cancer.

Kaya S., Aktas B., Tanrikulu Sismek E., Akif Ozturk M., Dede F., Kaya H., et al.
Journal of B.U.ON. : official journal of the Balkan Union of Oncology , vol.22, no.5, pp.1191-1198, 2017 (SCI-Expanded, Scopus)

140. Evaluation of non-invasive diagnostic methods as indicators of fibrosis in patients with nonalcoholic fatty liver disease

Atay K., Canbakan B., Alan Ö., Koroglu E., Hatemi I., Kepil N., et al.
BIOMEDICAL RESEARCH-INDIA , no.2, pp.565-570, 2017 (SCI-Expanded) Sustainable Development
Papers Presented at Peer-Reviewed Scientific Conferences 48

1. İMMÜN KONTROL NOKTASI İNHİBİTÖRLERİNE BAĞLI HEMOFAGOSİTİK LENFOHİSTİYOSİTOZ: FAERS VERİLERİ

Güzel S. S., Atak S., Çiçek E., Demirci N. S., Alan Ö.
13. Türk Tıbbi Onkoloji Kongresi, Antalya, Turkey, 22 - 26 April 2026, pp.78, (Summary Text) Creative Commons License

2. METASTATİK KASTRASYON-DUYARLI PROSTAT KANSERİNDE ALKALEN FOSFATAZIN BAĞIMSIZ PROGNOSTİK DEĞERİ

Aliyev V., Alan Ö.
13. Türk Tıbbi Onkoloji Kongresi, Antalya, Turkey, 22 - 26 April 2026, pp.59-60, (Summary Text) Creative Commons License

3. İLERİ EVRE OVER KANSERİNDE GRIM SKORUNUN KEMOTERAPİ YANITI VE SAĞKALIM ÜZERİNE ETKİSİ

Birsin Z., Günaltılı ., Demirci N. S., Alan Ö.
13. Türk Tıbbi Onkoloji Kongresi, Antalya, Turkey, 22 - 26 April 2026, pp.53-54, (Summary Text) Creative Commons License

4. İLERİ EVRE OVER KANSERLİ HASTALARDA VÜCUT KİTLE İNDEKSİNİN PROGNOSTİK ETKİSİ

Atak S., Çiçek E., Alan Ö.
13. Türk Tıbbi Onkoloji Kongresi, Antalya, Turkey, 22 - 26 April 2026, pp.110, (Summary Text) Creative Commons License

5. ENDOMETRİUM SERÖZ KARSİNOMDA ÇOKLU TEDAVİ SONRASI TRANSTUZUMAB DERUXTECAN İLE TAM YANIT: BİR OLGU SUNUMU

Çiçek E., Alan Ö.
13. Türk Tıbbi Onkoloji Kongresi, Antalya, Turkey, 22 - 26 April 2026, pp.128, (Summary Text) Creative Commons License

6. 65 YAŞ VE ÜZERİ METASTATİK RENAL HÜCRELİ KARSİNOM HASTALARINDA PANINFLAMMATORY VALUE’NİN PROGNOSTİK ÖNEMİ

Işık S., Alan Ö.
ON TARGED MASTER ONCOLOGY, Antalya, Turkey, 13 - 17 May 2026, pp.50-51, (Summary Text) Creative Commons License

7. İLERİ EVRE EPİTELİAL OVER KANSERİNDE NEOADJUVAN KEMOTERAPİ KÜR SAYISININ SAĞKALIM ÜZERİNE ETKİSİ: TEK MERKEZ DENEYİMİ

Birsin Z., Demirci N. S., Alan Ö.
ON TARGED MASTER ONCOLOGY, Antalya, Turkey, 13 - 17 May 2026, pp.150-152, (Summary Text) Creative Commons License

8. GASTROİNTESTİNAL SİSTEM MALİGNİTELERİNDE KLİNİK ÖZELLİKLER, LABORATUVAR BULGULARI VE MORTALİTE: SOLİD TÜMÖRLERLE KARŞILAŞTIRMALI ANALİZ

Güzel S. S., Demirci N. S., Alan Ö.
Kanserde Güncel Gelişmeler 2026 – Gastrointestinal Kanserler Sempozyumu, Konya, Turkey, 6 - 07 June 2026, pp.10-11, (Summary Text) Creative Commons License

9. 543eP - Can baseline immune inflammation predict outcomes? The role of the pan-immune inflammation value in HR-positive, HER2-negative metastatic breast cancer treated with CDK4/6 inhibitors

Cebeci S., Birsin Z., Jeral S., Abbasov H., Aliyev V., Cerme E., et al.
ESMO BREAST CANCER 2026, Berlin, Germany, 6 - 08 May 2026, pp.70-71, (Summary Text)

10. CDK4/6 INHIBITÖRLERI ILE ILIŞKILI RENAL VE ELEKTROLIT ADVERS OLAYLARIN FAERS TABANLI DISPROPORSIYONEL ANALIZI

Mütiş Alan A., Alan Ö.
Uluslararası Katılımlı 15. Güncel Böbrek Hastalıkları ve 10. Hipertansiyon, Nefroloji, Diyaliz ve Transplantasyon Kongresi, Muğla, Turkey, 22 - 26 April 2026, pp.90-91, (Summary Text) Creative Commons License

11. Meme Kanseri Hastalarında Alpelisib ve Capivasertib Kullanımına bağlı Advers Olay Profillerinin FAERS Tabanlı Karşılaştırılması: Isı Haritası ve UMAP ile Çok Boyutlu Analiz

Jeral Evinç S., Alan Ö.
6.Meme Kanseri Sempozyumu, İstanbul, Turkey, 6 - 08 February 2026, pp.20-22, (Summary Text)

12. CDK4/6 İnhibitörleri ile Tedavi Edilen Metastatik Meme Kanserinde PIV Skoru Prognostik Bir Belirteç Midir?

Cebeci S., Birsin Z., Jeral Evinç N. S., Alan Ö.
6.Meme Kanseri Sempozyumu, İstanbul, Turkey, 6 - 07 February 2026, pp.28, (Summary Text)

13. Erkek Meme Kanserinde Klinikopatolojik Özellikler: Tek Merkez Deneyimi

Çiçek E., Günaltılı M., Alan Ö.
6.Meme Kanseri Sempozyumu, İstanbul, Turkey, 6 - 08 February 2026, pp.27, (Summary Text)

14. Hedefe Yönelik Uzun Yolculuk: İleri Kalp Yetmezliği Eşliğinde Metastatik HR+ Meme Kanserinde Üç Yıllık Alpelisib Başarısı

Güzeş S. S., Alan Ö., Demirci N. S.
6.Meme Kanseri Sempozyumu, İstanbul, Turkey, 6 - 08 February 2026, pp.18-19, (Summary Text)

15. İkili Anti-HER2 Blokajı Alan Metastatik HER2-Pozitif Meme Kanserli Hastalarda Dosetaksel Kür Sayısının Sağkalım Üzerine Etkisi

Birsin Z., Çiçek E., Demirci N. S., Alan Ö.
6.Meme Kanseri Sempozyumu, İstanbul, Turkey, 6 - 08 February 2026, pp.19-20, (Summary Text)

16. METASTATIK MIDE KANSERINDE KLINIK, NUTRISYONEL VE İNFLAMATUAR BELIRTEÇLERIN PROGNOSTIK ÖNEMI: TEK MERKEZ RETROSPEKTIF ANALIZ

Aliyev V., Günaltılı M., Alan Ö.
9.ULUSAL İMMÜNOTERAPİ ve ONKOLOJİ KONGRESİ, Güzelyurt, Cyprus (Kktc), 29 October - 02 November 2025, pp.52-53, (Summary Text) Creative Commons License

17. EVRE II KOLON KANSERI: CHATGPT DAHA YOĞUN ADJUVAN TEDAVI MI ÖNERIYOR? MDT KARARLARI ILE KARŞILAŞTIRMA

Birsin Z., Cebeci S., Jeral N. S., Alan Ö.
9.ULUSAL İMMÜNOTERAPİ ve ONKOLOJİ KONGRE, Güzelyurt, Cyprus (Kktc), 29 October - 02 November 2025, pp.36, (Summary Text) Creative Commons License

18. Immune checkpoint inhibitors and hemophagocytic lymphohistiocytosis: Disproportionality analysis from FAERS

Güzel S. S., Atak S., Çiçek E., Demirci N. S., Alan Ö.
ESMO Immuno-Oncology Congress 2025, London, England, 10 - 12 December 2025, pp.12, (Summary Text) Creative Commons License

19. Immune-mediated upper gastrointestinal system toxicities in patients receiving immune checkpoint inhibitors: An analysis of the food and drug administration adverse event reporting system (FAERS)

Çerme E., Guliyev M., Aliyev V., Birsin Z., Günaltılı M., Fidan M. C., et al.
ESMO Immuno-Oncology Congress 2025, London, England, 10 - 12 December 2025, pp.30, (Summary Text) Creative Commons License

20. 2928eP Characteristics and outcomes of kidney transplant rejection associated with immune checkpoint inhibitors: A FAERS database analysis

Alan Ö., Mutis Alan A.
ESMO 2025, Berlin, Germany, 17 October - 21 November 2025, pp.1535, (Summary Text) Creative Commons License

21. Prognostic value of systemic inflammatory markers in advanced soft tissue sarcoma patients treated with trabectedin: A retrospective analysis

Jeral S., Eyüpler Ç., Birsin Z., Nazlı İ., Güren A. K., Köylü B., et al.
ESMO 2025, Berlin, Germany, 17 - 21 October 2025, pp.1462, (Summary Text) Creative Commons License

22. 3005P Radioiodine-refractory differentiated thyroid cancer (RAI-R DTC) patients treated with sorafenib monotherapy: Real-world treatment patterns and clinical outcomes in Türkiye

Alan Ö.
ESMO 2025, Berlin, Germany, 17 - 21 October 2025, pp.1565, (Summary Text) Creative Commons License

23. YATARAK TEDAVI GÖREN İLERI EVRE KANSER HASTALARINDA MORTALITEYI ÖNGÖREN FAKTÖRLER: TERSIYER MERKEZ DENEYIMI

Güzel S. S., Atak S., Çakan Z. K., Demirci N. S., Alan Ö.
2.avrasya interdisipliner onkoloji kongresi, Gazimagusa, Cyprus (Kktc), 1 - 05 October 2025, pp.126-127, (Summary Text)

24. VÜCUT KITLE İNDEKSI’NIN PCR ÜZERINE BAĞIMSIZ ETKISI: HER2-POZITIF EVRE II–III MEME KANSERINDE RETROSPEKTIF ÇALIŞMA

Birsin Z., Günaltılı M., Alan Ö.
2.avrasya interdisipliner onkoloji kongresi, Gazimagusa, Cyprus (Kktc), 1 - 05 October 2025, pp.69-70, (Summary Text)

25. HORMON POZITIF, HER2 NEGATIF (HR+/ HER2-) METASTATIK MEME KANSERINDE (MMK) CDK4/6 INHIBITÖRÜ TEDAVISI ALAN HASTALARDA YAŞA GÖRE TOKSISITE PROFILI VE DOZ MODIFIKASYONLARI: GERÇEK YAŞAM VERILERI

Fidan M. C., Alan Ö.
2.avrasya interdisipliner onkoloji kongresi, Gazimagusa, Cyprus (Kktc), 1 - 05 October 2025, pp.54-55, (Summary Text)

26. SACITUZUMAB GOVITECAN, TRASTUZUMAB EMTANSINE VE TRASTUZUMAB DERUXTECAN ILE İLIŞKILI İNTERSTISYEL AKCIĞER HASTALIĞI: FAERS VERITABANI ANALIZI

Jeral Evinç S., Eyüpler Akmercan Ç., Cebeci S., Birsin Z., Aliyev V., Günaltılı M., et al.
2. Avrasya İnterdisipliner Onkoloji Kongresi, Gazimagusa, Cyprus (Kktc), 1 - 05 October 2025, pp.40-41, (Summary Text) Creative Commons License

27. Incidence and Frequency of Immune-Related Nephropathy in Patients Treated with Immune Checkpoint Inhibitors A FAERS Database Analysis (2020–2024)

Mütiş Alan A., Alan Ö.
62nd ERA Congress , Vienna, Austria, 4 - 07 June 2025, pp.3330, (Summary Text) Creative Commons License

28. İmmün Kontrol Noktası İnhibitörleri ile İlişkili Böbrek Nakli Rejeksiyonu Olgularının Klinik Özellikleri ve Sonuçları: FAERS Veritabanı Analizi

Mütiş Alan A., Alan Ö.
4. Cerrahpaşa İç Hastalıkları & 3. İç Hastalıkları Hemşireliği Kongresi, İstanbul, Turkey, 5 - 07 September 2025, pp.18-19, (Summary Text) Creative Commons License

29. Yaygın Evre Küçük Hücreli Akciğer Kanserinde İmmunoterapinin Rolü: Atezolizumab Deneyimi

Cebeci S., Birsin Z., Jeral Evinç N. S., Alan Ö., Demirci N. S.
3. Onkolojide Yenilikler Sempozyumu, Girne, Cyprus (Kktc), 16 - 18 May 2025, (Unpublished)

30. IMMÜN KONTROL NOKTASI INHIBITÖRLERI ILE TEDAVI EDILEN HASTALARDA IMMÜN ILIŞKILI NEFROPATININ SIKLIĞI: BIR FAERS DATABASE ANALIZI (2020–2024)

Mütiş Alan A., Alan Ö., Dinçer M. T., Murt A., Altıparmak M. R., Seyahi N., et al.
Uluslararası Katılımlı 14. Güncel Böbrek Hastalıkları ve 9. Hipertansiyon, Nefroloji, Diyaliz ve Transplantasyon Kongresi, Muğla, Turkey, 23 - 27 April 2025, pp.85, (Summary Text) Creative Commons License

31. LOKAL VE LOKAL İLERİ EVRE HER2 POZİTİF MEME KANSERİNDE NEOADJUVAN TEDAVİYE YANITI ETKİLEYEN FAKTÖRLER

Birsin Z., Cebeci S., Çiçek E., Jeral N. S., Demirci N. S., Papila Ç., et al.
12. Türk Tıbbi Onkoloji Kongresi, Antalya, Turkey, 23 - 27 April 2025, pp.224-225, (Summary Text) Creative Commons License

32. Metastatik Akciğer, Meme ve Prostat kanserli hastalarda denosumab ve zoledronik asit tedavilerinin etkinliğinin retrospektif olarak incelenmesi

Aliyev V., Alan Ö.
Hedef Kanser 2025, Girne, Cyprus (Kktc), 20 - 23 March 2025, (Unpublished) Creative Commons License

33. REAL-WORLD DATA ON THE EFFICACY AND SAFETY OF RAMUCIRUMAB PLUS PACLITAXEL EITHER ALONE OR IN COMBINATION WITH IMMUNOTHERAPY IN PATIENTS WITH PREVIOUSLY TREATED ADVANCED GASTRIC ADENOCARCINOMA

Köylü B., Kıkılı İ., Alan Ö., Selçukbiricik F., Laçin Ş.
14th International Gastrointestinal Cancers Conference (IGICC2024)), İstanbul, Turkey, 28 November - 01 December 2024, pp.7-8, (Full Text) Creative Commons License

34. EFFICACY AND SAFETY OF DURVALUMAB PLUS CHEMOTHERAPY IN PATIENTS WITH ADVANCED BILIARY TRACT CANCER: A MULTICENTER REALWORD DATA FROM TURKISH ONCOLOGY GROUP

Efil S. C., Şendur M. A. N., Kuş F., Bayram S., Köylü B., Araz M., et al.
14th International Gastrointestinal Cancers Conference (IGICC2024), İstanbul, Turkey, 28 November - 01 December 2024, pp.25-26, (Full Text) Creative Commons License

35. PERIOPERATIVE NIVOLUMAB COMBINED WITH NEOADJUVANT CHEMOTHERAPY IN LOCALLY ADVANCED GASTRIC/GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA: TWO-CENTER EXPERIENCE

Köylü B., Kıkıllı İ., Selçukbiricik F., Alan Ö., Laçin Ş., Yumuk F., et al.
14th International Gastrointestinal Cancers Conference (IGICC2024)), İstanbul, Turkey, 28 November - 01 December 2024, pp.6, (Full Text) Creative Commons License

36. UZMAN HEKIMLERIN KANSER TARAMA PROGRAMLARI HAKKINDAKI EĞILIM ANKET SONUÇLARI/TOG ÇALIŞMASI

Özdemir Ö., Nayır E., Gürbüz M., Türk H. M., Demiray A. G., Çağlayan ., et al.
11. Türk Tıbbi Onkoloji Kongresi, Girne, Cyprus (Kktc), 24 - 28 April 2024, pp.71-72, (Summary Text) Creative Commons License

37. LOKAL ILERI GASTRIK/GASTROÖZEFAGEAL BILEŞKE ADENOKARSINOMLARINDA NEOADJUVAN IMMUNOTERAPI: İKI MERKEZ DENEYIMI

Köylü B., Selçukbiricik F., Alan Ö., Laçin Ş., Yumuk F., Kanıtez M., et al.
11. Türk Tıbbi Onkoloji Kongresi’, Girne, Cyprus (Kktc), 24 - 28 April 2024, pp.60-61, (Summary Text) Creative Commons License

38. GASTROINTESTINAL TÜMÖRLERDE MULTIDISIPLINER TÜMÖR KONSEYI SONUÇLARI TEK MERKEZ DENEYIM

Bayram Kuvvet B., Alan Ö., Akbaş ., Celayir M., Babashov F., Erel ., et al.
10. Türk Tıbbi Onkoloji Kongresi, Antalya, Turkey, 26 - 30 April 2023, pp.47, (Full Text) Creative Commons License

39. ERIŞKIN NÖROBLASTOM VAKASI-NADIR BIR OLGU SUNUMU

Alan Ö., Bayram Kuvvet B., Altıntaş Y. E., Koçak S., Selçukbiricik F.
10. Türk Tıbbi Onkoloji Kongresi’, Antalya, Turkey, 26 - 30 April 2023, pp.124-125, (Summary Text) Creative Commons License

40. İMMUNOTERAPI İLIŞKILI NÖROLOJIK YAN ETKILERIN DEĞERLENDIRILMESI: TEK MERKEZ DENEYIMI

Altıntaş Y. E., Bayram Kuvvet ., Çelebi O., Koçak S., Bülbül M. C., Alan Ö., et al.
10. Türk Tıbbi Onkoloji Kongresi, Antalya, Turkey, 26 - 30 April 2023, pp.46-47, (Full Text) Creative Commons License

41. Does insulin resistance predict complete response in breast cancer patients who underwent neoadjuvant treatment?

ALAN Ö., Telli T. A., Aktas B., Koca S., Okten I. N., Tuylu T. B., et al.
42nd Annual San Antonio Breast Cancer Symposium, San-Antonio, Northern Mariana Islands, 9 - 14 December 2019, (Summary Text)

42. Ribociclib for the treatment of hormone receptor-positive refractory advanced breast cancer: Managed access programme in Turkey

Demirci U., GÖKMEN E., Eralp Y., Gunduz S., SEZGİN GÖKSU S., KORKMAZ T., et al.
42nd Annual San Antonio Breast Cancer Symposium, San-Antonio, Northern Mariana Islands, 9 - 14 December 2019, (Summary Text)

43. Comparison of three different chemotherapy regimens for concomitant chemoradiotherapy in locally advanced non-small cell lung cancer

Isikogan A., Akdeniz N., Kucukoner M., Kaplan M. A., Urakci Z., Karhan O., et al.
44th Congress of the European-Society-for-Medical-Oncology (ESMO), Barcelona, Spain, 27 September - 01 October 2019, pp.595, (Summary Text)

44. Neoadjuvant treatment in patients with locally advanced gastric cancer.

GÜMÜŞ M., Kaya S., Eris S., ALAN Ö., Telli T. A., Okten I. N., et al.
Gastrointestinal Cancers Symposium, San-Francisco, Costa Rica, 17 - 19 January 2019, (Summary Text) Sustainable Development

45. The efficacy and safety of crizotinib in patients with ROS1 positive advanced stage NSCLC: The real-world experience from Turkey

Kilickap S., ÖLMEZ Ö. F., ÇİÇİN İ., Demirci U., ALAN Ö., ÇABUK D., et al.
43rd ESMO Congress (ESMO), Munich, Germany, 19 - 23 October 2018, pp.505, (Summary Text)

46. Modified Glasgow prognostic score, prognostic nutritional index and ECOG score could be new prognostic factors for survival in metastatic gastric cancer

Demirelli B., Babacan N., Koca S., Uzun B. N., Ercelep O., ÖZTÜRK M., et al.
42nd European-Society-for-Medical-Oncology Congress (ESMO), Madrid, Spain, 8 - 12 September 2017, (Summary Text)

47. Analysis of survival and prognostic factors in metastatic colorectal cancer patients treated with first line bevacizumab.

Demircan N., Dane F., Ozturk M. A., Besiroglu M., Babacan N., Kaya S., et al.
53rd Annual Clinical Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, United States Of America, 2 - 07 June 2017, (Summary Text) Sustainable Development

48. Changes in 18F-FDG-PET/CT tumor metabolism and prediction of pathologic complete response rates after neoadjuvant chemotherapy in hormone-positive breast cancer.

Kaya S., Aktas B., Simsek E. T., Ozturk M. A., DEDE F., Kaya H., et al.
Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, United States Of America, 3 - 07 June 2016, (Summary Text)
Books 5

1. Akciğer Kanserleri

Alan Ö., Yumuk P. F.
in: İç Hastalıkları, Dr. Gürler İLİÇİN,Kadir BİBEROĞLU,Gültekin SÜLEYMANLAR,Serhat ÜNAL, Editor, Güneş Kitabevi, Ankara, pp.1693-1698, 2024 Creative Commons License

2. Parotisin Malign Tümörlerinde Adjuvan Tedavi Yaklaşımları Adjuvant Treatment for Malignant Parotid Tumors

Atasoy B. M., Üçüncü Kefeli A., Alan Ö.
in: KulaK Burun Boğaz ÖZEL KONULAR, Günter HAFIZ,Selçuk GÜNEŞ, Editor, Türkiye Klinikleri Yayınevi, Ankara, pp.70-76, 2021 Creative Commons License

3. KANSER TEDAVİSİNDE İMMUNOTERAPİ

Alan Ö.
in: Onkolojik Aciller , Tarkan Yetişyiğit,Serhat Örün, Editor, Akademisyen Yayınevi Kitabevi, İstanbul, pp.67-77, 2020 Creative Commons License

4. GlioblastomdaNüksHastalıkta SistemikTedaviSeçenekleri-

Alan Ö., Yumuk F.
in: Erişkin Santral Sinir Sistemi Tümörleri, PerranFulden YUMUK, Editor, Türkiye Klinikleri Yayınevi, Ankara, pp.61-65, 2019 Creative Commons License

5. MESANE KANSERİNİN NEOADJUVAN/ADJUVAN TEDAVİSİNDE GÜNCEL DURUM

Alan Ö., Öztürk M. A.
in: Mesane ve Üst Üriner Sistem Kanserleri, Kamil Çam, Editor, Türkiye Kanserle Savaş Vakfı, Ankara, pp.84-86, 2016 Creative Commons License
Metrics

Publication

195

Publication (WoS)

125

Publication (Scopus)

118

Citation (WoS)

146

H-Index (WoS)

7

Citation (Scopus)

468

H-Index (Scopus)

10

Citation (Scholar)

10

H-Index (Scholar)

2

Citation (TrDizin)

4

H-Index (TrDizin)

1

Citation (Sobiad)

1

H-Index (Sobiad)

1

Citation (Sum Other)

4

Total Citation Count

155

Thesis Advisory

1

Open Access

75
UN Sustainable Development Goals
SDG 3: GOAL 3: GOOD HEALTH AND WELL-BEING